Cardiology News / Recent Literature Review / Last Quarter 2015 by Manolis, Antonis S & Anninos, Hector
14 
 
Cardiology News / Recent Literature Review / 
Last Quarter 2015 
 
Antonis S. Manolis, MD, Hector Anninos, MD 
Athens University School of Medicine, Athens, Greece   
Rhythmos 2016;11(1):14-25.    
Boston AF Symposium: Orlando, 14-16/1/2016  
ACC 65th Annual Session: Chicago, 2-4/4/2016  
HRS 37th Annual Meeting: San Francisco, 4-7/5/16  
CardioStim/Europace: Nice, 8-11/6/2016  
Euro PCR: Paris, 17-20/5/2016  
ESC Meeting: Rome, 27-31/8/2016   
Targeting Ablation to the Distal Segment of the 
Main Renal Artery and Post-Bifurcation Branches 
May Optimize Renal Denervation (RDN) 
Insufficient procedural efficacy has been proposed to 
explain nonresponse to renal denervation (RDN). The 
impact of different patterns of lesion placements on the 
efficacy and consistency of catheter-based radiofrequency 
(RF) RDN was examined in pigs. Increasing the number of 
RF lesions (4, 8, and 12) in the main renal artery was not 
sufficient, but targeted treatment of the renal artery 
branches or distal segment of the main renal artery resulted 
in markedly less variability of response and significantly 
greater reduction of both norepinephrine (NE) and axon 
density than conventional treatment of only the main renal 
artery. Combination treatment (main artery plus branches) 
produced the greatest change in renal NE and axon density 
with the least heterogeneity. The changes lasted through 
28 days post-treatment (Mahfoud F et al, J Am Coll 
Cardiol 2015;66:1766-1775).   
High Levels of Cardiorespiratory Fitness in Midlife 
Confer Lower Mortality, Use of Health Care 
Resources, and Health Care Costs Later in Life  
Among 19,571 healthy individuals who underwent 
cardiorespiratory fitness assessment at a mean age of 49 
years, over 126,388 person-years of follow-up, average 
annual health care costs were significantly lower for 
participants aged >65 years with high than low midlife 
fitness in both men and women. Average annual health 
care costs in later life were incrementally lower per MET 
achieved in midlife in men and women. The authors 
concluded that higher cardiorespiratory fitness in middle 
age is strongly associated with lower health care costs at 
an average of 22 years later in life, independent of 
cardiovascular risk factors (Bachmann JM et al, J Am Coll 
Cardiol 2015;66:1876-1885).  
Moderate Physical Activity is Associated with a 
Reduced Risk of Atrial Fibrillation (AF) in Middle-
Aged and Elderly Women 
According to a Swedish study comprising 36,513 AF-
free women (aged 49–83, median 60 years) during a 
median of 12 years, 2915 cases of AF were diagnosed. The 
risk of AF decreased with increasing levels of leisure-time 
exercise at study entry (relative risk - RR 0.85, for ≥4 
h/week vs <1 h/week) and walking/bicycling (RR 0.81, for 
≥40 min/day vs almost never) (Drca N et al, Heart 
2015;101:1627-1630).   
Very Late Thrombosis of Bioresorbable Coronary 
Scaffolds Despite Antiplatelet Therapy, Possibly 
Related to Scaffold Discontinuity and Restenosis, 
Implies an Extended Period of Vulnerability to 
Ischemic Events  
Four patients presented with very late scaffold 
thrombosis (VLScT) at 44, 19 (2 cases), and 21 months, 
after implantation of an Absorb Bioresorbable Vascular 
Scaffold. At the time of VLScT, all patients were taking 
low-dose aspirin, and 2 patients were also taking prasugrel. 
Optical coherence tomography (OCT) showed malapposed 
scaffold struts surrounded by thrombus in 7.1%, 9%, and 
8.9% of struts in 3 cases. Scaffold discontinuity with struts 
in the lumen center was the cause of malapposition in 2 
cases. Uncovered scaffold struts with superimposed 
thrombus were the predominant findings in 1 case. OCT 
percent area stenosis at the time of VLScT was high in 2 
cases (71-75%) without evidence of excessive neointimal 
hyperplasia. Thrombus aspirate analysis showed 
persistence of intracoronary polymer fragments in 1 case 
(Räber L et al, J Am Coll Cardiol 2015;66:1901-1914).   
Meta-Analysis: Macrolide Antibiotics Increase Rates 
of Ventricular Tachyarrhythmias, Sudden Cardiac 
Death, and Cardiovascular Death, but not All-Cause 
Deaths  
Meta-analysis of 33 studies involving 20,779,963 
participants indicated that patients who took macrolides, 
compared with those who did not, experienced an 
increased risk of developing sudden cardiac death (SCD) 
or ventricular tachyarrhythmias (VTAs) (relative risk - 
RR: 2.42), SCD (RR: 2.52), and cardiovascular death (RR: 
1.31). No association was found between macrolides use 
and all-cause death or any cardiovascular events. The RRs 
associated with SCD or VTAs were 3.40 for azithromycin, 
2.16 for clarithromycin, and 3.61 for erythromycin, 
respectively. RRs for cardiovascular death were 1.54 for 
azithromycin and 1.48 for clarithromycin. No association 
was noted between roxithromycin and adverse cardiac 
outcomes (Cheng Y-J et al, J Am Coll Cardiol 2015;66: 
2173-2184).   
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Most Patients With Symptomatic Carcinoid Valvular 
Heart Disease Have Symptom and Survival Benefit 
from Valve Replacement Especially when Operated 
Before Advanced Right-Sided Heart Failure Develops 
Among 195 patients with carcinoid heart disease 
(CaHD) (70% NYHA class III or IV), all having tricuspid 
valve replacement (159 bioprostheses, 36 mechanical), 
and 157 pulmonary valve operation, with 4-23% also 
having other concomitant operations, there were 20 
perioperative deaths (10%). After year 2000, perioperative 
mortality was 6%. Survival rates at 1, 5, and 10 years were 
69%, 35%, and 24%, respectively. Overall mortality was 
associated with older age, cytotoxic chemotherapy, and 
tobacco use; 75% of survivors had symptomatic 
improvement at follow-up (Connolly HM et al, J Am Coll 
Cardiol 2015;66:2189-2196).   
ROCKET AF: In Patients With Atrial Fibrillation 
(AF) and Additional Stroke Risk Factors, Anti-
coagulation With Rivaroxaban is Associated With a 
Higher Rate of Major or Non-Major GI Bleeding than 
Warfarin, but Similar Rate of Most Severe GI Bleeding  
Among 14,236 patients, 684 experiencing 
gastrointestinal (GI) bleeding during follow-up, there was 
a significantly higher rate of major or non-major clinical 
GI bleeding in rivaroxaban- vs warfarin-treated patients 
(3.61 events/100 patient-years vs 2.60 events/100 patient-
years; hazard ratio: 1.42). Severe GI bleeding rates were 
similar between treatment arms, and fatal GI bleeding 
events were rare. Independent clinical factors most 
strongly associated with GI bleeding were baseline 
anemia, history of GI bleeding, and long-term aspirin use 
(Sherwood MW et al, J Am Coll Cardiol 2015;66:2271-
2281).   
In Patients With Severe, Symptomatic Secondary 
Tricuspid Regurgitation (TR) at High Risk for 
Surgery, Transcatheter Reduction Therapy May be an 
Acceptable Alternative Strategy  
The transcatheter Forma Repair System (Edwards 
Lifesciences, Irvine, Ca, USA), designed to provide a 
surface for native leaflet coaptation to reduce TR by 
occupying the regurgitant orifice area, was employed via 
the left axillary vein in 7 high-risk patients with severe TR 
and clinical signs of heart failure (NYHA class II-IV) who 
were declined for surgery (logistic EuroSCORE 25.7 ± 
17.4%). The device consists of a spacer (a foam-filled 
polymer balloon) and a rail that is anchored at the right 
ventricular apex. Device implantation was successful 
without procedural complications in all patients, with 
significant reductions in TR severity (moderate in 3 and 
mild in 4 patients). Median hospital stay was 4 days. At 30 
days, all patients but 1 had improvement in NYHA status 
(to class II) with marked reduction in peripheral edema and 
moderate TR (Campelo-Parada F et al, J Am Coll Cardiol 
2015;66:2475-2483).  
CRT-D is Associated with a Lower Risk of Heart 
Failure Hospitalization or Death Among Patients With 
Stages 3-5 Chronic Kidney Disease, Including Those on 
Dialysis, Than Management With Defibrillators Alone  
Among 10,946 cardiac resynchronization therapy 
(CRT)-eligible patients (ejection fraction<35%, QRS >120 
ms, NYHA class III/IV) with stage 3 to 5 chronic kidney 
disease (CKD), CRT-D use (n=9,525) compared with ICD 
only (n=1421) was associated with a reduction in heart 
failure (HF) hospitalization or death (hazard ratio - HR: 
0.84; p< 0.0001), death (HR: 0.85; p<0.0004), and HF 
hospitalization alone (HR: 0.84; p< 0.009). Subgroup 
analyses suggested that CRT was associated with a 
reduced risk of HF hospitalization and death across CKD 
classes. The incidence of in-hospital, short-term, and mid-
term device-related complications did not vary across 
CKD stages (Friedman DJ et al, J Am Coll Cardiol 
2015;66:2618-2629).   
NORDIC ICD Trial: Defibrillation Testing During 
Initial ICD Implantation is no Longer Required for 
Routine Left-Sided ICD Implantation 
Among 1077 patients having initial ICD implantation 
with (n = 540) or without (n = 537) defibrillation (DF) 
testing (all ICD shocks programmed to 40 J irrespective of 
DF test results), over a mean of 22.8 months, first shock 
efficacy (FSE) was found to be non-inferior in patients 
with an ICD implanted without a DF test, with a difference 
in FSE of 3% in favour of the no-DF test (Pnon-inferiority 
<0.001 for the pre-defined non-inferiority margin of 
−10%). A total of 112 procedure-related serious adverse 
events occurred within 30 days in 94 patients (17.6%) 
tested compared with 89 events in 74 patients (13.9%) not 
tested (P = 0.095) (Bänsch D et al, Eur Heart J 2015; 36: 
2500-2507).  
In Patients With Ventricular Arrhythmias (VAs) that 
Exhibit LBBB and Inferior Axis, Pace Mapping in the 
RV Outflow Tract (RVOT) May not Identify the VA 
Focus. In Such Patients, Particularly When Ablation 
Has Failed, Mapping Performed at the Pulmonary 
Sinus Cusp (PSC) Identifies VAs that Can be 
Successfully Ablated  
Among 218 patients undergoing successful endocardial 
ablation of idiopathic VAs with a left bundle branch block 
(LBBB) morphology and inferior axis, 24 patients had 
VAs originating from the PSC. In the first 7, initial ablation 
performed in the RVOT failed but produced a small 
change in the QRS morphology in 3 patients. In all 24 
patients, the earliest activation was eventually identified in 
the PSC, where a sharp potential was recorded preceding 
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the QRS onset by 28.2 ± 2.9 ms. The successful ablation 
site was in the right cusp (RC) in 10 patients (42%), the 
left cusp (LC) in 8 (33%), and the anterior cusp (AC) in 6 
(25%). ECG analysis showed that RC-VAs had unique 
ECG characteristics (larger R-wave in lead I and a smaller 
aVL/aVR ratio of Q-wave amplitude compared with AC-
VAs and LC-VAs; R-wave amplitude in inferior leads was 
smaller in VAs localized in the RC than in the LC but did 
not differ between VAs from the AC and LC (Liao Z et al, 
J Am Coll Cardiol 2015;66:2633-2644).  
Revascularization, not Necessarily by PCI, of Chronic 
Total Occlusion (CTO), is Associated with Improved 
Long-Term Survival Relative to Medical Therapy  
Among 1957 patients, a CTO was treated by PCI in 405 
(20.7%), medical therapy in 667 (34.1%), and coronary 
bypass in 885 (45.2%) patients. Of those treated by PCI or 
medical therapy, propensity score matching identified 294 
pairs of patients; PCI was successful in 177 patients 
(60.2%). All-cause mortality at 5 years was 11.6% for 
CTO PCI and 16.7% for medical therapy, hazard ratio-HR 
0.63 (p=0.052). The composite of 5-year death or MI 
occurred in 13.9% of the CTO PCI group and 19.6% in the 
medical therapy group, HR 0.64 (p=0.043). Among the 
CTO PCI group, if CTO was revascularized by any means, 
5-year mortality was 10.6% vs 18.3% in those not 
revascularized in the medical therapy group, HR 0.50 
(p=0.016) (Ladwiniec A et al; Heart 2015;101:1907-
1914).   
CvLPRIT Cardiovascular Magnetic Resonance (CMR) 
Substudy: In Patients With STEMI and Multivessel 
Disease, Complete Revascularization is Associated with 
a Small Increase (12%) in the Risk of Type 4a MIs, but 
Similar Total Infarct Size, Compared With a Strategy 
Addressing Only the Infarct-Related Artery (IRA) 
Among 203 of the 296 patients in the main trial (98 
complete revascularization and 105 IRA-only), having a 
pre-discharge CMR, total infarct size was similar in the 
two groups. The complete revascularization group had an 
increase in non-IRA MI on the pre-discharge CMR (22 of 
98 vs 11 of 105, p= 0.02). There was no difference in total 
infarct size or ischemic burden between treatment groups 
at follow-up CMR (McCann GP et al, J Am Coll Cardiol 
2015;66:2713-2724).   
CHASE-AF: Pulmonary Vein Isolation (PVI) Should 
be the Initial Strategy of Ablation in Patients With 
Persistent AF, Because More Extensive Ablation Has 
no Better Rhythm Control Outcomes  
Two strategies of catheter ablation were compared in 
205 patients (mean age 62 years) with persistent atrial 
fibrillation (AF): pulmonary vein isolation (PVI) and a 
stepwise approach (full defrag) of PVI, ablation of 
complex fractionated electrograms, and additional linear 
ablation lines for atrial tachycardias in patients with 
persistent AF after PVI. Patients were prospectively 
randomized to either PVI alone (n = 78) or full defrag (n = 
75), with 52 patients not randomized due to AF termination 
with the original PVI. A total of 241 ablations were 
performed (mean: 1.59 in the PVI-alone group, 1.55 in the 
full-defrag group). With the stepwise approach, 
termination of AF occurred in 45 (60%) patients. However, 
arrhythmia-free survival did not differ whether patients 
underwent single or multiple procedures (p=NS). 
Procedure duration, fluoroscopy time, and radiofrequency 
duration were significantly longer in the full-defrag group 
(all p<0.001) (Vogler J et al, J Am Coll Cardiol 2015;66: 
2743-2752).  
New Oral Anticoagulants (NOACs) and Left Atrial 
Appendage Closure (LAAC) are Cost-Effective Over 
Warfarin for Stroke Risk Reduction in Patients With 
Nonvalvular AF / LAAC Proved to be the Most Cost-
Effective Treatment  
Using a Markov model and information from 
PROTECT AF 4-year data and meta-analyses of warfarin 
and NOACs, it was shown that relative to warfarin, LAAC 
was cost-effective at 7 years ($42,994/quality-adjusted 
life-years - QALY), and NOACs were cost-effective at 16 
years ($48,446/QALY). LAAC was dominant over 
NOACs by year 5 and warfarin by year 10. At 10 years, 
LAAC gave more QALYs than warfarin and NOACs 
(5.855 vs 5.601 vs 5.751, respectively). In sensitivity 
analyses, LAAC remained cost-effective relative to 
warfarin ($41,470/QALY at 11 years) and NOACs 
($21,964/QALY at 10 years) (Reddy VY et al, J Am Coll 
Cardiol. 2015;66:2728-2739).  
VISTA Trial: Substrate-Based Ablation is Superior to 
Targeting Only Clinical and Stable Ventricular 
Tachycardias (VTs) in Ischemic Cardiomyopathy, and 
Confers a Significant Reduction of Combined 
Incidence of Rehospitalization and Mortality  
Subjects with ischemic cardiomyopathy and 
hemodynamically stable VT were randomized to clinical 
ablation (n= 60) vs substrate-based ablation that targeted 
all “abnormal” electrograms in the scar (n= 58). At 1 year, 
9 (15.5%) in the substrate-based and 29 (48.3%) patients 
in the clinical VT ablation group had VT recurrence (p< 
0.001). More patients undergoing clinical VT ablation 
(58%) were on antiarrhythmic drugs after ablation vs 
substrate-based ablation (12%; p< 0.001). Seven (12%) 
patients with substrate ablation and 19 (32%) with clinical 
ablation required rehospitalization (p= 0.014). Mortality at 
1 year was 11.9%; 8.6% in the substrate ablation and 15% 
in the clinical ablation group (p = 0.21). Combined 
incidence of rehospitalization and mortality was 
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significantly lower with substrate ablation (p = 0.003). 
Periprocedural complications were similar (p=NS) (Di 
Biase L et al, J Am Coll Cardiol 2015;66:2872-2882).   
EVEREST II: The 5-Year Results Support the 
Superiority of Surgery in Reducing Mitral 
Regurgitation (MR) but Also the Long-Term Safety of 
the Mitraclip and the Durability of MR Reduction 
After Percutaneous Repair / Although Patients Treated 
With Percutaneous Repair More Commonly Required 
Surgery for Residual MR in the First Year, Between 
Years 1-5, there were Comparably Low Rates of 
Surgery for Valve Dysfunction  
In EVEREST II, treatment of MR with the MitraClip 
showed superior safety compared with surgery, but less 
effective reduction in MR at 1 year. At 5 years, the rate of 
the composite endpoint of freedom from death, surgery, or 
3+/4+ MR in the as-treated population was 44.2% in the 
percutaneous repair and 64.3% in the surgical group (p= 
0.01); difference driven by increased rates of 3+ to 4+ MR 
(12.3% vs 1.8%; p= 0.02) and of surgery (27.9% vs 8.9%; 
p=0.003) with percutaneous repair. After percutaneous 
repair, 78% of surgeries were performed within the first 6 
months. Beyond 6 months, rates of surgery and moderate-
to-severe MR were comparable between groups; as well as 
5-year mortality rates (20.8% and 26.8%) (Feldman T et 
al, J Am Coll Cardiol 2015;66:2844-2854).   
CURRENT AS Registry: Earlier Aortic Valve 
Replacement (AVR) in Patients With Asymptomatic 
Severe Aortic Stenosis (AS) is Associated with Lower 
Long-Term Risk of Hospitalization for HF or All-
Cause Mortality Compared With Currently 
Recommended by Guidelines to Await Symptom Onset  
Data from 1,808 asymptomatic severe AS patients 
having AVR (n=291) or conservative strategies (n=1,517) 
and from a propensity score–matched cohort of 582 
patients (n= 291 in each group) indicated that the 
cumulative 5-year incidences of all-cause death (15.4% vs 
26.4%, p= 0.009) and heart failure (HF) hospitalization 
(3.8% vs 19.9%, p< 0.001) were significantly lower in the 
initial AVR group. In the conservative group, AVR was 
performed in 41% of patients during follow-up (Taniguchi 
T et al, J Am Coll Cardiol 2015;66:2827-2838).   
STS/ACC TVT Registry: Technological Advances in 
Device Configuration, Smaller Catheter Sizes, and 
Patient-Specific Access Site Selection Can Lower Risk 
of Extracardiac Complications in Patients Undergoing 
TAVI/ However, these Patients Have Multiple Co-
morbidities, Including Advanced Age, and the Risk of 
Periprocedural Stroke Remains an Important Concern  
Comparison of 2 time periods (2012 & 2013) among 
26,414 TAVI procedures (by 31/12/2014) in TVT Registry 
revealed that TAVI patients remain elderly (mean age 82), 
with multiple comorbidities reflected by a high mean STS 
score (8.34%), were highly symptomatic (NYHA class 
III/IV in ~83%), frail (slow 5-m walk test in ~82%), and 
have poor self-reported health status. Procedure 
performance is changing, with an increased use of 
moderate sedation (from 1.6% to 5.1%) and increase in 
femoral access (~67% in 2014). Vascular complication 
rates are decreasing (from 5.6% to 4.2%), whereas site-
reported stroke rates remain stable at 2.2% (Holmes DR et 
al, J Am Coll Cardiol 2015;66:2813-2823).   
FreezeAF Study: Noninferiority of Cryoballoon (CB) 
Versus Open Irrigated Radiofrequency (RF) Ablation 
in Patients With Paroxysmal Atrial Fibrillation (PAF) 
A total of 315 PAF patients were randomly assigned to 
RF (n=159) or CB (n=156) ablation. Freedom from 
arrhythmia with absence of persistent complications at 1 
year was achieved by 70.7% with RF and 73.6% with CB 
(multiple procedure success), including 31 redo 
procedures in each group (19.5% of RF vs 19.9% of CB; 
P=NS). Rates at 6 months were 63.1% and 64.1% for the 
RF and CB groups (single procedure success), and 
noninferiority was confirmed (risk difference, 0.010; 
P=0.002). Periprocedural complications for the index 
procedure were more frequent in the CB group (5% RF, 
12.2% CB; P=0.022) with a significant difference in 
phrenic nerve palsies (0% RF, 5.8% CB; P=0.002) (Luik 
A et al, Circulation 2015; 132: 1311-1319).  
Meta-Analysis of Case-Control Studies: Significant 
Association Between Recent Respiratory Infection and 
Acute Myocardial Infarction (AMI) / Estimated 
Vaccine Effectiveness Against AMI was Comparable 
with the Efficacy of Currently Accepted Therapies for 
Secondary Prevention of AMI  
According with 16 case–control studies (8 on influenza 
vaccination, 10 on influenza infection and AMI), recent 
influenza infection, influenza-like illness or respiratory 
tract infection was more likely in AMI cases, with a pooled 
odds ratio - OR 2.01. Influenza vaccination was associated 
with AMI, with a pooled OR of 0.71, equating to an 
estimated vaccine effectiveness of 29% against AMI 
(Barnes M et al, Heart 2015;101:1738-1747).   
Treatment With Colchicine in Patients With STEMI 
Undergoing Primary PCI is Associated With Smaller 
Infarct Size, as Defined by Both Biomarker Release 
and MRI-Late Gadolinium Enhancement (LGE)  
Patients (n=151) presenting with ST-segment–
elevation myocardial infarction (STEMI) ≤12 hours from 
pain onset (treated with primary PCI) were randomly 
assigned to colchicine (n=77) or placebo (n=74) for 5 days. 
A subset of patients (n=60) underwent cardiac MRI-LGE 
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6-9 days after the index STEMI. The area under the CK-
MB curve was 3144 ng·h–1·mL–1 in the colchicine group 
vs 6184 ng·h–1·mL–1 in controls (P<0.001). Indexed MRI–
LGE defined infarct size was 18.3 mL/1.73 m2 in the 
colchicine group (n=31) vs 23.2 mL/1.73 m2 in controls 
(n=29) (P=0.019). The relative infarct size (as a proportion 
to left ventricular myocardial volume) was 13% and 
19.8%, respectively (P=0.034) (Deftereos S et al, 
Circulation 2015; 132: 1395-1403).   
Taiwanese Database: Risk of Mortality was Lower for 
AF Patients Receiving Rate-Control With Β-Blockers 
or Calcium Channel Blockers (Β-Blockers Conferred 
the Largest Risk Reduction), While Digoxin Use was 
Associated With Greater Mortality 
Over a mean of ~5 years, among 43,879 patients with 
atrial fibrillation (AF) receiving β-blockers, 18,466 
receiving calcium blockers, and 38,898 receiving digoxin, 
88,263 patients (32.7%) died. Compared to a reference 
group of 168,678 subjects who did not receive any rate-
control drug, the risk of mortality was lower in patients 
receiving β-blockers (hazard ratio – HR =0.76) and 
calcium channel blockers (HR=0.93). On the contrary, the 
digoxin group had a higher risk of mortality with an HR of 
1.12 (Chao T-F et al, Circulation 2015; 132: 1604-1612).   
WEARIT-II Registry: High Rate of Sustained 
Ventricular Tachyarrhythmias (VTAs) at 3 Months in 
Patients At-Risk Who are not Eligible for an ICD / The 
Wearable Cardioverter Defibrillator (WCD) Can 
Protect Patients During this Period  
A total of 2000 patients (median age 62 years; median 
ejection fraction 25%) with ischemic (n=805, 40%), or 
nonischemic cardiomyopathy (n=927, 46%), or congenital 
/inherited heart disease (n=268) received a wearable 
cardioverter defibrillator (WCD) for a median of 90 days, 
with median daily use of 22.5 h. There was a total of 120 
sustained VTAs in 41 patients, of whom 54% received 
appropriate WCD shock (10 patients or 0.5% received 
inappropriate therapy). Rate of sustained VTAs by 3 
months was 3% among patients with ischemic cardio-
myopathy and congenital/inherited heart disease, and 1% 
among nonischemic patients (P=0.02). Finally, 840 
patients (42%) were implanted with an ICD. The most 
frequent reason not to implant an ICD following WCD use 
was improvement in ejection fraction (Kutyifa V et al, 
Circulation 2015; 132: 1613-1619).   
Descending Thoracic or Thoracoabdominal Aortic 
Aneurysm: Risk of Rupture Starts to Increase With a 
Diameter >5.0 - 5.5 cm / Uncertain Whether Aneurysm 
Repair in this Range Leads to Overall Benefit 
Of 257 patients (age, 72.4±10.5 years; 143 women) 
with descending thoracic or thoracoabdominal aortic 
aneurysm (baseline mean maximal diameter 52.4±10.8 
mm, with 103 patients having diameters ≥55 mm) without 
a history of aortic dissection in whom surgical intervention 
was not undertaken, over 2 years, definite and possible 
aortic events occurred in 19 (7.4%) and 31 (12.1%) 
patients, respectively. Maximal aortic diameter at baseline 
was the only significant predictor of aortic events (hazard 
ratio=1.12). Estimated rates of definite aortic events within 
1 year were 5.5%, 7.2%, and 9.3% for aortic diameters of 
50, 55, and 60 mm, respectively (Kim JB et al, Circulation 
2015; 132: 1620-1629).   
Meta-analysis: Doses of Physical Activity (PA) in 
Excess of the Guideline-Recommended Minimum PA 
Levels May be Required for More Substantial 
Reductions in Heart Failure (HF) Risk 
In 12 prospective cohort studies with 20,203 HF events 
among 370,460 patients (53.5% women; median follow-
up, 13 years), the highest levels of PA were associated with 
reduced risk of HF (hazard ratio – HR for highest vs lowest 
PA, 0.70). Compared with patients reporting no leisure-
time PA, those who engaged in guideline-recommended 
minimum levels of PA (500 MET-min/wk; 2008 US 
guidelines) had modest reductions in HF risk (HR, 0.90). 
However, a higher risk reduction was observed among 
patients who engaged in PA at twice (HR for 1000 MET-
min/wk, 0.81) and 4 times (HR for 2000 MET-min/wk, 
0.65) the minimum guideline-recommended levels 
(Pandey A et al, Circulation 2015; 132: 1786-1794).   
CARDIA Study: Higher Intake of Fruits and 
Vegetables (F/V) During Young Adulthood was 
Associated With Lower Odds of Prevalent Coronary 
Artery Calcium After 20 Years of Follow-Up / 
Important to Establish a High Intake of F/V as Part of 
a Healthy Dietary Pattern Early in Life 
Among the study participants (n=2506) (mean age at 
baseline 25.3 years; 62.7% female), higher intake of F/V 
was associated with a lower prevalence of coronary artery 
calcium (measured at year 20 using computed 
tomography): odds ratio - OR, 0.78, and 0.74, from the 
lowest to the highest tertile of F/V, P value for trend 
<0.001. There was attenuation of the association between 
F/V and coronary artery calcium after adjustment for other 
dietary variables, but the trend remained significant: OR, 
0.84, and 0.92, P value for trend <0.002 (Miedema MD et 
al, Circulation 2015; 132: 1990-1998).   
PATH Registry: Better Survival and Neurological 
Outcome With Therapeutic Hypothermia for Post–
Cardiac Arrest Patients with an Initial Nonshockable 
Rhythm 
Among 519 patients after in- and out-of-hospital 
cardiac arrest with nonshockable initial rhythms, 201 
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propensity score–matched pairs (mean age 63±17 years, 
51% male; 60% with initial pulseless electric activity) 
were compared. Survival to hospital discharge was greater 
in patients who received therapeutic hypothermia (TH) 
(17.6% vs 28.9%; P<0.01), as was a discharge Cerebral 
Performance Category of 1 to 2 (13.7% vs 21.4%; P=0.04). 
Patients who received TH were more likely to survive 
(odds ratio, 2.8) and to have better neurological outcome 
(odds ratio, 3.5) than those that did not receive TH (Perman 
SM et al, Circulation 2015; 132: 2146-2151).   
Outcomes are Better with Basic (BLS) than Advanced 
Life Support (ALS) for Several Out-of-Hospital 
Medical Emergencies   
In a 20% random sample of Medicare beneficiaries 
from non-rural areas with major trauma, stroke, acute 
myocardial infarction (AMI), or respiratory failure, except 
in cases of AMI, patients showed superior outcomes with 
BLS despite being older and having more comorbidities. 
In propensity score analysis, survival to 90 days among 
patients with trauma, stroke, and respiratory failure was 
higher with BLS than ALS (6.1% points for trauma; 7% 
points for stroke; and 3.7% points for respiratory failure). 
Patients with AMI did not have differences in survival at 
30 days but had better survival at 90 days with ALS (1% 
point). Neurologic functioning favored BLS for all 
diagnoses. Instrumental variable analysis for trauma and 
stroke had similar results, showed no survival differences 
between BLS and ALS for respiratory failure, and showed 
better survival at all time points with BLS than ALS for 
patients with AMI (Sanghavi P et al, Ann Intern Med. 
2015;163:681-690).  
Potassium Channel Blockade May Enhance Atrial 
Fibrillation (AF)–Selective Antiarrhythmic Effects of 
Optimized State-Dependent Sodium Channel Blockade 
In a mathematical model, combining optimized Na+-
channel blocker with IKr block increased rate-dependent 
and atrium-selective peak INa reduction, increased AF 
selectivity, and more effectively terminated AF compared 
with optimized Na+-channel blocker alone. Combining 
optimized Na+-channel blocker with IKur block had similar 
effects but without IKr block–induced ventricular action 
potential prolongation. Consistent with the mathematical 
model, in coronary-perfused canine hearts, the addition of 
dofetilide (selective IKr blocker) to pilsicainide (selective 
INa blocker) produced enhanced atrium-selective effects on 
maximal phase 0 upstroke and conduction velocity. 
Furthermore, pilsicainide plus dofetilide had higher AF 
termination efficacy than pilsicainide alone. Pilsicainide 
alone had no significant effect on AF inducibility, whereas 
pilsicainide plus dofetilide rendered AF noninducible 
(Aguilar M et al, Circulation 2015; 132: 2203-2211).   
3 Large Prospective Cohorts: Higher Consumption of 
Coffee, either Caffeinated or Decaffeinated, was 
Associated With Lower Risk of Total Mortality 
The associations of consumption of total, caffeinated, 
and decaffeinated coffee with risk of subsequent total and 
cause-specific mortality were examined among 74,890 
women in the Nurses’ Health Study (NHS), 93,054 women 
in the Nurses’ Health Study II, and 40,557 men in the 
Health Professionals Follow-up Study. During 4,690,072 
person-years of follow-up, 19,524 women and 12,432 men 
died. Compared with nondrinkers, coffee consumption of 
1-5 cups/day was associated with lower risk of mortality, 
whereas coffee consumption of >5 cups/day was not. 
However, when restricting to never smokers compared 
with nondrinkers, the hazard ratios of mortality were 0.94 
for <1 cup/day, 0.92 for 1.1 to 3.0 cups/day, 0.85 for 3.1-
5.0 cups/day, and 0.88 for >5 cups per day (P value for 
trend < 0.001). Significant inverse associations were 
observed for caffeinated (P < 0.001) and decaffeinated 
coffee (P = 0.022). Significant inverse associations were 
observed between coffee consumption and deaths 
attributed to cardiovascular disease, neurologic diseases, 
and suicide. No significant association between coffee 
consumption and total cancer mortality was found (Ding 
M et al, Circulation 2015; 132: 2305-2315).  
 
Among Patients With Continuous-Flow Left 
Ventricular Assist Devices, Restoration of Pulsatile 
Flow Through Modulations in Pump Speed Leads to 
Decline in Muscle Sympathetic Nerve Activity (MSNA) 
Reductions in pump speed in 13 patients (10 men / 3 
women, 54±14 years) with Heartmate II continuous-flow 
left ventricular assist devices led to increases in pulse 
pressure (high vs low speed: 17±7 vs 26±12 mm Hg; 
P<0.01), distension of the carotid artery, and carotid 
arterial wall tension (P<0.05 for all measures). In addition, 
MSNA was reduced (high vs low speed: 41±15 vs 33±16 
bursts/minute; P<0.01) despite a reduction in mean arterial 
pressure and was inversely related to pulse pressure 
(P=0.037) (Cornwell WK et al, Circulation 2015; 132: 
2316-2322).  
 
40-Year Analysis of >500 Patients With Primary 
Malignant Cardiac Tumors (PMCTs): MPCTs are 
Extremely Rare and Continue to be Associated With 
Poor Prognosis / Over the Past 5 Decades, Incidence 
and Survival Appear to Have Increased 
From a total of 7,384,580 cases of cancer registered in 
the National Cancer Institute, 551 PMCTs (0.008%) were 
identified with an incidence of 34 cases per 100 million 
persons, increased over time (25.1 in 1973–1989, 30.2 in 
1990–1999, and 46.6 in 2000–2011). Most patients are 
female (54.1%) and white (78.6%) with median age at 
diagnosis of 50 years. The most common PMCTs are 
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sarcomas (n=357, 64.8%), lymphomas (n=150, 27%) and 
mesotheliomas (n=44, 8%), mostly diagnosed with biopsy 
(96.8%). Use of chemotherapy is not documented; 19% 
received radiation and 44% had surgery. After a median of 
80 months, 413 patients had died. The 1-, 3-, and 5-year 
survival rates were 46%, 22%, and 17% and have 
improved over the eras, with 1-, 3-, and 5-year survival 
rates of 32%, 17%, and 14% for 1973-1989 and 50%, 24%, 
and 19% for 2000-2011 (P=0.009). Cardiac sarcomas and 
mesotheliomas are the most lethal PMCTs. Patients with 
cardiac lymphomas and sarcomas are younger and have 
worse survival than patients with extracardiac disease of 
similar histopathology (P<0.001) (Oliveira GH et al, 
Circulation 2015; 132: 2395-2402).  
 
Transvenous Lead Removal (TLR): Complication Rate 
in Patients Undergoing TLR was Higher Than 
Previously Reported Related to Female Gender and 
Device Infections but not to Hospital Volume  
Among 91,890 TLR procedures in the US, in-hospital 
death (2.2%), hemorrhage requiring transfusion (2.6%), 
vascular complications (2.0%), pericardial complications 
(1.4%), open heart surgery (0.2%), and postoperative 
respiratory failure (2.4%) were recorded. Independent 
predictors of complications were female gender and device 
infections. Hospital volume was not independently 
associated with higher complications. There was a 
significant rise in overall complication rates over the study 
period (Deshmukh A et al, Circulation 2015; 132: 2363-
2371).  
 
TUXEDO–India Trial: In Patients With Diabetes and 
Coronary Artery Disease Undergoing PCI, Paclitaxel-
Eluting Stents were Inferior to Everolimus-Eluting 
Stents, with Higher Rates of Target-Vessel Failure, 
Myocardial Infarction, Stent Thrombosis, and Target-
Vessel Revascularization at 1 Year 
Among 1830 patients with diabetes and coronary artery 
disease who were undergoing PCI randomly assigned to 
receive either a paclitaxel-eluting stent or an everolimus-
eluting stent, at 1 year, paclitaxel-eluting stents did not 
meet the criterion for noninferiority to everolimus-eluting 
stents with respect to the primary end point (rate of target-
vessel failure, 5.6% vs 2.9%; relative risk, 1.89; P=0.38 for 
noninferiority). There was a higher 1-year rate in the 
paclitaxel-eluting stent group of target-vessel failure 
(P=0.005), spontaneous myocardial infarction (3.2% vs 
1.2%, P=0.004), stent thrombosis (2.1% vs 0.4%, 
P=0.002), target-vessel revascularization (3.4% vs 1.2%, 
P=0.002), and target-lesion revascularization (3.4% vs 
1.2%, P=0.002) (Kaul U et al, N Engl J Med 2015; 
373:1709-1719).  
 
ABSORB III Study: Everolimus-Eluting Bioresorbable 
Scaffolds are Non-Inferior to Everolimus-Eluting 
Cobalt–Chromium Stents with Respect to Target-
Lesion Failure (Cardiac Death, Target-Vessel 
Myocardial Infarction, or Ischemia-Driven Target-
Lesion Revascularization) at 1 Year 
Among 2008 patients with stable or unstable angina 
assigned to receive an everolimus-eluting bioresorbable 
vascular (Absorb) scaffold (n=1322) or an everolimus-
eluting cobalt–chromium (Xience) stent (n=686), target-
lesion failure at 1 year occurred in 7.8% in the Absorb and 
6.1% in the Xience group (P=0.007 for noninferiority; 
P=0.16 for superiority). There was no significant 
difference between the Absorb and the Xience group in 
cardiac death (0.6% vs 0.1%; P=NS), target-vessel MI 
(6.0% vs 4.6%; P=NS), or ischemia-driven target-lesion 
revascularization (3% vs 2.5%; P=NS). Device thrombosis 
within 1 year occurred in 1.5% in the Absorb group and in 
0.7% in the Xience group (P=NS) (Ellis SG et al, N Engl J 
Med 2015; 373:1905-1915).  
 
BIOSOLVE-II First-In-Man Trial: Implantation of the 
Second-Generation Drug-Eluting Absorbable Metal 
Scaffold (DREAMS 2G Device) in De-Novo Coronary 
Lesions is Feasible, With Favourable Safety and 
Performance Outcomes at 6 Months, and Could be an 
Alternative to Absorbable Polymeric Scaffolds 
In 123 patients (123 lesions) receiving a novel second-
generation drug-eluting absorbable metal scaffold 
(DREAMS 2G), at 6 months, in-segment late lumen loss 
was 0.27+0.37 mm, and angiographically discernable 
vasomotion was documented in 20 (80%) of 25 patients. 
Intravascular ultrasound showed a preservation of the 
scaffold area (6.24+1.15 mm2 post-procedure vs 6.21+1.22 
mm2 at 6 months) with a low neointimal area (0.08+0.09 
mm2), and optical coherence tomography did not detect 
any intraluminal mass. Target lesion failure occurred in 4 
(3%) patients: one (<1%) patient died from cardiac death, 
1 (<1%) patient had periprocedural MI, and 2 (2%) patients 
needed clinically driven target lesion revascularization. No 
definite or probable scaffold thrombosis was observed 
(Haude M et al, Lancet 2016; 387, No. 10013:31–39).  
 
A Cohort US Study on Early Repolarization: J Waves 
and QRS Slurs did not Exhibit an Increased Risk for 
Cardiovascular Death in Long-Term Follow-up 
In veterans <56 years (~90% men) who had resting 12-
lead ECG, over a median follow-up of 17.5 years, 859 
cardiovascular deaths occurred. Of 20,661 ECGs, 4219 
(20%) had J waves or QRS slurs in the inferior (3318 or 
78.6%) and/or lateral leads (1701 or 40.3%). The upper 
bound of differences in risk for cardiovascular death from 
any of the J-wave or QRS slur patterns suggests that an 
increased risk can be safely ruled out (inferior, −0.77%; 
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lateral, −1.07%) (Pargaonkar VS et al, Ann Intern Med 
2015;163:747-755).  
 
COURAGE Trial (15-Year Follow-up): Among 
Patients With Stable Ischemic Heart Disease, Objective 
Evidence of Ischemia, Significant Coronary Disease, 
and a Substantial Risk of Death (Mortality ~4%/Year), 
there was no Difference in Long-Term Survival With 
an Initial Strategy of Optimal Medical Therapy Plus 
PCI Compared With Optimal Medical Therapy Alone 
In the COURAGE trial, an initial management strategy 
of optimal medical therapy alone compared with optimal 
medical therapy plus PCI among 2287 patients with stable 
ischemic heart disease did not differ in clinical outcome 
over a median follow-up period of 4.6 years. Extended (15-
year) survival information was available for 1211 patients 
(53% of the original group). The median follow-up for all 
patients was 6.2 years (range, 0-15). A total of 561 deaths 
(180 during the follow-up period in the original trial and 
381 during the extended follow-up period) occurred: 284 
deaths (25%) in the PCI group and 277 (24%) in the 
medical-therapy group (adjusted hazard ratio, 1.03; P=NS) 
(Sedlis SP et al, N Engl J Med 2015; 373:1937-1946).  
 
LEADERS FREE: Among Patients at High Bleeding 
Risk Who Underwent PCI, a Polymer-Free 
Umirolimus (Biolimus A9)-Coated Stent was Superior 
to a Bare-Metal Stent When Used With a 1-Month 
Course of Dual Antiplatelet Therapy 
A total of 2466 patients at high bleeding risk 
undergoing PCI, were randomized to a drug-coated stent 
or a bare-metal stent. The drug-coated stent was a polymer-
free drug-coated stent that transfers umirolimus (biolimus 
A9), a highly lipophilic sirolimus analogue, into the vessel 
wall over 1 month. All patients received 1 month of dual 
antiplatelet therapy. At 390 days, the primary safety end 
point (cardiac death, MI, or stent thrombosis) occurred in 
112 patients (9.4%) in the drug-coated–stent group and in 
154 patients (12.9%) in the bare-metal–stent group (hazard 
ratio - HR, 0.71; P<0.001 for noninferiority; P=0.005 for 
superiority). During the same period, clinically driven 
target-lesion revascularization was needed in 59 patients 
(5.1%) in the drug-coated–stent group and in 113 patients 
(9.8%) in the bare-metal–stent group (HR, 0.50; P<0.001) 
(Urban P et al, N Engl J Med 2015; 373:2038-2047).  
 
Possible Subclinical Leaflet Thrombosis in 
Bioprosthetic Aortic Valves Suspected from Reduced 
Leaflet Motion Detected by 4-Dimensional, Volume-
Rendered CT / Therapeutic Anticoagulation With 
Warfarin, but not Therapy With Antiplatelet Drugs, 
Prevented and Effectively Treated This Phenomenon 
Data obtained from 55 patients in a clinical trial of 
TAVI and from 2 registries that included 132 patients who 
were undergoing either transcatheter (TAVI) or surgical 
aortic-valve bioprosthesis implantation showed reduced 
leaflet motion noted on computed tomography (CT) in 22 
of 55 patients (40%) in the clinical trial and in 17 of 132 
patients (13%) in the 2 registries. Therapeutic 
anticoagulation with warfarin, as compared with dual 
antiplatelet therapy, decreased the incidence of reduced 
leaflet motion (0% and 55%, respectively, P=0.01 in the 
clinical trial; and 0% and 29%, respectively, P=0.04 in the 
pooled registries). In patients who were reevaluated with 
follow-up CT, restoration of leaflet motion was noted in all 
11 patients who were receiving anticoagulation and in 1 of 
10 patients who were not (P<0.001). There was no 
significant difference in the incidence of stroke or TIA 
between the two groups in the clinical trial (2 of 22 patients 
and 0 of 33 patients, respectively; P=NS), but in the 
registries, a significant difference was detected (3 of 17 
patients and 1 of 115 patients, respectively; P=0.007) 
(Makkar RR et al, N Engl J Med 2015; 373:2015-2024).  
 
SPRINT Trial: Intensive (<120 mmHg) vs Standard 
(<140 mmHg) Blood-Pressure (BP) Control is Superior 
in Patients at High Risk for Cardiovascular Events but 
Without Diabetes, Albeit With Higher Rates of Some 
Adverse Events  
Patients (n=9361) with a systolic BP of >130 mmHg 
and an increased cardiovascular risk, but without diabetes, 
were randomized to a systolic BP target of <120 mmHg 
(n=4678, intensive treatment) or a target of <140 mmHg 
(n=4683, standard treatment). At 1 year, the mean systolic 
BP was 121.4 mm Hg in the intensive-treatment and 136.2 
mmHg in the standard-treatment group. Trial was stopped 
early (median 3.26 years) due to significantly lower rate of 
the primary composite outcome (myocardial infarction, 
other acute coronary syndromes, stroke, heart failure, or 
death from cardiovascular causes) in the intensive-
treatment group (1.65% vs 2.19%/year; hazard ratio - HR, 
0.75; P<0.001). All-cause mortality was also significantly 
lower in the intensive-treatment group (HR, 0.73; 
P=0.003). Rates of serious adverse events (hypotension, 
syncope, electrolyte abnormalities, and acute kidney injury 
or failure, but not of traumatic falls) were higher in the 
intensive-treatment group (SPRINT Research Group, N 
Engl J Med 2015; 373:2103-2116).  
 
EMPA-REG OUTCOME Trial: Empagliflozin 
(Inhibitor of Sodium–Glucose Cotransporter 2) Added 
to Standard Care Confers Cardiovascular Benefit in 
Patients with Type 2 Diabetes  
A total of 7020 patients were randomly treated with 10 
mg or 25 mg of empagliflozin or placebo (median 
observation time, 3.1 years). The primary outcome (death 
from cardiovascular causes, nonfatal MI, or nonfatal 
stroke) occurred in 490 of 4687 patients (10.5%) in the 
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pooled empagliflozin group and in 282 of 2333 patients 
(12.1%) in the placebo group (hazard ratio, 0.86; P=0.04 
for superiority). There were no significant between-group 
differences in the rates of MI or stroke, but in the 
empagliflozin group there were significantly lower rates of 
death from cardiovascular causes (3.7%, vs 5.9% in the 
placebo group; 38% relative risk reduction), 
hospitalization for heart failure (2.7% and 4.1%, 
respectively; 35% relative risk reduction), and death from 
any cause (5.7% and 8.3%, respectively; 32% relative risk 
reduction). There was no significant between-group 
difference in the secondary outcome (primary outcome 
plus hospitalization for unstable angina) (P=0.08 for 
superiority). Among patients receiving empagliflozin, 
there was an increased rate of genital infection but no 
increase in other adverse events (Zinman B et al, N Engl J 
Med 2015; 373:2117-2128).  
 
Toxic Central Obesity (NHANES III): Normal-Weight 
Central Obesity is associated with Higher Mortality 
than BMI-Defined (but no Central) Obesity  
Among 15,184 adults (aged 18-90 years; 52% women), 
persons with normal-weight central obesity had the worst 
long-term survival: a man with a normal BMI (22 kg/m2) 
and central obesity had greater total mortality risk than one 
with similar BMI but no central obesity (hazard ratio - HR, 
1.87), and this man had twice the mortality risk of those 
who were overweight or obese by BMI only (HR, 2.24 & 
2.42, respectively). Women with normal-weight central 
obesity also had a higher mortality risk than those with 
similar BMI but no central obesity (HR, 1.48) and those 
who were obese according to BMI only (HR, 1.32). 
Expected survival estimates were consistently lower for 
those with central obesity when age and BMI were 
controlled for (Sahakyan KR et al, Ann Intern Med. 
2015;163:827-835).  
 
ROC Trial: In Patients With Out-Of-Hospital Cardiac 
Arrest, Continuous Chest Compressions During CPR 
did not Result in Significantly Higher Rates of Survival 
or Favorable Neurologic Function than did 
Interrupted Chest Compressions 
Of 23,711 adults with non–trauma-related cardiac 
arrest, 12,653 were assigned to continuous chest 
compressions (intervention group) and 11,058 to 
interrupted chest compressions at a ratio of 30 
compressions to 2 ventilations (control group). A total of 
1129 of 12,613 patients with available data (9%) in the 
intervention group and 1072 of 11,035 (9.7%) in the 
control group survived until discharge (P=0.07); 7% of the 
patients in the intervention group and 7.7% of those in the 
control group survived with favorable neurologic function 
at discharge (P=0.09). Hospital-free survival was 
significantly shorter in the intervention group than in the 
control group (P=0.004) (Nichol G et al, N Engl J Med 
2015; 373:2203-2214).  
 
ANNEXA-A and ANNEXA-R Trials: Andexanet Alfa 
Reversed the Anticoagulant Activity of Factor Xa 
Inhibitors, Apixaban and Rivaroxaban, in Older 
Healthy Participants Within Minutes After 
Administration and for the Duration of Infusion, 
Without Evidence of Clinical Toxic Effects 
Healthy older (mean age 58 years) volunteers were 
given 5 mg of apixaban bid or 20 mg of rivaroxaban qd. 
Andexanet was administered as a bolus or as a bolus plus 
a 2-h infusion. Among the apixaban-treated participants, 
anti–factor Xa activity was reduced by 94% with 
andexanet bolus (n=24), vs 21% with placebo (n=9) 
(P<0.001), and unbound apixaban concentration was 
reduced by 9.3 ng/ml vs 1.9 ng/ml (P<0.001); thrombin 
generation was fully restored in 100% vs 11% of the 
participants (P<0.001) within 2-5 min. Among the 
rivaroxaban-treated participants, anti–factor Xa activity 
was reduced by 92% with andexanet bolus (n=27) vs 18% 
with placebo (n=14) (P<0.001), and unbound rivaroxaban 
concentration was reduced by 23.4 ng/ml vs 4.2 ng/ml 
(P<0.001); thrombin generation was fully restored in 96% 
vs 7% of the participants (P<0.001). These effects were 
sustained with andexanet bolus plus infusion. In a 
subgroup, transient increases in levels of D-dimer and 
prothrombin fragments 1 and 2 were observed, which 
resolved within 24-72 h. No serious adverse or thrombotic 
events were reported (Siegal DM et al, N Engl J Med 2015; 
373:2413-2424).  
 
IPD-Work Consortium: Long Working Hours Increase 
Risk of Stroke and Less So Coronary Heart Disease 
Risk / More Attention Should Be Paid to the 
Management of Vascular Risk Factors in Individuals 
Who Work Long Hours  
Meta-analysis of 25 studies comprised data for 603,838 
men and women who were free from coronary heart 
disease at baseline, and data for 528,908 men and women 
who were free from stroke at baseline. Mean follow-up for 
coronary heart disease was 8.5 years, in which 4768 events 
were recorded, and for stroke 7.2 years, in which 1722 
events were recorded. Compared with standard hours (35–
40 h/week), working long hours (≥55 h/week) was 
associated with an increase in risk of coronary heart 
disease (relative risk - RR 1.13; p=0.02) and stroke (1.33; 
p=0.002). A dose–response association was recorded for 
stroke, with RR estimates of 1.10 (p=0.24) for 41–48 
working hours, 1.27 (p=0.03) for 49–54 working hours, 
and 1.33 (p=0.002) for >55 working hours/week compared 
with standard working hours (ptrend<0·0001) (Kivimaki M 
et al, Lancet 2015; 386 (No. 10005):1739–1746).  
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REVERT Trial: Postural Modification of Valsalva 
Maneuver Increases Conversion of Supraventricular 
Tachycardias (SVT) from 17% to 43% 
A modified Valsalva maneuver (done semi-recumbent 
with supine repositioning and passive leg raise 
immediately after the Valsalva strain) (n=214) was 
compared with a nonmodified version of the maneuver 
(n=214) in 428 patients presenting with SVT. 37 (17%) of 
those assigned to standard Valsalva achieved sinus rhythm 
compared with 93 (43%) of 214 in the modified Valsalva 
maneuver group (odds ratio 3.7; p<0·0001) (Appelboam A 
et al, Lancet 2015; 386, No. 10005:1747–1753).  
 
FAME Study 5-Year Follow-Up: Fractional Flow 
Reserve (FFR)-Guided PCI Conferred a Decrease of 
Major Adverse Cardiac Events for up to 2 Years, at 2-
5 Years the Risks Were Similar / This Outcome was 
Achieved With a Lower Number of Stented Arteries 
and Less Resource Use / FFR Guidance of Multivessel 
PCI Could be the Standard of Care in Most Patients  
In FAME, fractional flow reserve (FFR)-guided 
percutaneous coronary intervention (PCI) (PCI done only 
if FFR was <0.80) improved outcome compared with 
angiography-guided PCI for up to 2 years of follow-up. 
After 5 years, major adverse cardiac events occurred in 
31% of patients (154 of 496) in the angiography-guided 
group vs 28% (143 of 509 patients) in the FFR-guided 
group (relative risk 0.91; p=NS). The number of stents 
placed per patient was significantly higher in the 
angiography-guided than in the FFR-guided group (mean 
2.7 vs 1.9, p<0.0001) (van Nunen LX et al, Lancet 2015; 
386, No. 10006:1853–1860).  
 
Spironolactone vs Placebo, Bisoprolol, and Doxazosin 
for Drug-Resistant Hypertension (PATHWAY-2): 
Spironolactone was the Most Effective Add-On Drug, 
Supporting a Primary Role of Sodium Retention in 
Resistant Hypertension  
Patients (n=335), aged 18–79 years with seated clinic 
systolic blood pressure (BP) >140 mmHg (or ≥135 mm Hg 
for patients with diabetes) and home systolic BP (18 
readings over 4 days) >130 mmHg, despite treatment for 
at least 3 months with maximally tolerated doses of 3 
drugs, were rotated, in a preassigned, randomized order, 
through 12 weeks of once daily treatment with each of 
spironolactone (25–50 mg) (n=285), bisoprolol (5–10 mg) 
(n=285), doxazosin modified release (4–8 mg) (n=282), 
and placebo (n=274), in addition to their baseline BP 
drugs. The dose was doubled after 6 weeks of each cycle; 
230 patients completed all treatment cycles. The average 
reduction in home systolic BP by spironolactone was 
superior to placebo (–8.70 mmHg; p<0·0001), superior to 
the mean of the other 2 active treatments (doxazosin and 
bisoprolol; −4.26; p<0.0001), and superior when compared 
with the individual treatments; vs doxazosin (–4.03; 
p<0.0001) and vs bisoprolol (–4.48; p<0.0001). 
Spironolactone was the most effective BP-lowering 
treatment, throughout the distribution of baseline plasma 
renin; but its margin of superiority and likelihood of being 
the best drug for the individual patient were many-fold 
greater in the lower than higher ends of the distribution. 
All treatments were well tolerated. In 6 of the 285 patients 
who received spironolactone, serum potassium exceeded 6 
mmol/L on one occasion (Williams B et al, Lancet 2015; 
386, No. 10008:2059–2068).  
 
CLEAN Trial: Chlorhexidine–Alcohol Appears More 
Effective than Povidone Iodine–Alcohol as a Skin 
Antiseptic to Prevent Intravascular-Catheter-Related 
Infections, Albeit With More Severe Skin Reactions  
A total of 1181 patients (2547 catheters) were randomly 
assigned to 2% chlorhexidine–70% alcohol (594 patients 
with scrubbing, 587 without) and 1168 (2612 catheters) to 
5% povidone iodine–69% alcohol (580 patients with 
scrubbing, 588 without). Chlorhexidine–alcohol was 
associated with lower incidence of catheter-related 
infections (0.28 vs 1.77 per 1000 catheter-days with 
povidone iodine–alcohol; hazard ratio 0.15; p=0.0002). 
Scrubbing was not associated with a significant difference 
in catheter colonization (p=NS). No systemic adverse 
events were reported, but severe skin reactions occurred 
more frequently in those assigned to chlorhexidine–
alcohol (27 or 3% patients vs 7 or 1% with povidone 
iodine–alcohol; p=0.0017) and led to chlorhexidine 
discontinuation in 2 patients (Mimoz O et al, Lancet 2015; 
386, No. 10008:2069–2077).  
 
Review & Meta-Analysis: Transradial Access for 
Coronary Angiography and Percutaneous Coronary 
Intervention (PCI) is Associated with a Small but 
Significant Increase in Radiation Exposure in Both 
Diagnostic and Interventional Procedures Compared 
With Transfemoral Access / Differences in Radiation 
Exposure Narrowed Over Time 
Data from 24 randomized controlled trials (RCTs) for 
19,328 patients showed that transradial access was 
associated with a small but significant increase in 
fluoroscopy time for coronary angiograms (weighted mean 
difference - WMD, fixed effect: 1.04 min; p<0.0001) and 
PCI (1.15 min; p<0.0001), compared with transfemoral 
access. Transradial access was also associated with higher 
kerma (gray-Gy)-area product for coronary angiograms 
(WMD, fixed effect: 1.72 Gy·cm2; p=0.06), and higher 
kerma-area product for PCI (0.55 Gy·cm2; p=0.02). 
Operator radiation doses for PCI with basic protection 
were 107+110 μSv with transradial and 74+68 μSv with 
transfemoral access; with supplementary protection, the 
doses decreased to 21+17 μSv with transradial access and 
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46+9 μSv with transfemoral. Overall difference in 
fluoroscopy time between the 2 procedures has decreased 
significantly by 75% over the past 20 years from 2 min in 
1996 to ~30 s in 2014 (p<0.0001) (Plourde G et al, Lancet 
2015; 386, No. 10009: 2192–2203).  
 
High-STEACS Trial: Low Plasma Levels of High-
Sensitivity Troponin at Presentation in Patients With 
Suspected Acute Coronary Syndrome Identify Two-
Thirds of Patients at Very Low Risk of Cardiac Events 
Who Could be Discharged From Hospital  
According to a prospective study of 6304 consecutive 
patients with suspected acute coronary syndrome, 782 
(16%) of 4870 patients in the derivation cohort having MI, 
with a further 32 (1%) re-presenting with MI and 75 (2%) 
cardiac deaths at 30 days, in patients without MI at 
presentation, troponin concentrations were <5 ng/L in 
2311 (61%) of 3799 patients, with a negative predictive 
value of 99.6% for the primary outcome (MI or subsequent 
MI or cardiac death at 1 month). The negative predictive 
value was consistent across groups stratified by age, sex, 
risk factors, and previous cardiovascular disease. In two 
independent validation cohorts, troponin concentrations 
were <5 ng/L in 594 (56%) of 1061 patients, with an 
overall negative predictive value of 99.4%. At 1 year, these 
patients had a lower risk of MI and cardiac death than did 
those with a troponin concentration of >5 ng/L (0.6% vs 
3.3%; adjusted hazard ratio 0.41; p<0.0001) (Shah ASV et 
al, Lancet 2015; 386, No. 10012: 2481–2488).  
 
Danish Cohort Study: In a Real-World Cohort of 
Patients with a First Hospitalization for an Acute 
Coronary Syndrome (ACS), Early Invasive Treatment 
Strategy was Associated With a Lower Risk for 
Cardiac Death and Rehospitalization for MI 
Compared with a Conservative Invasive Approach 
In 19,704 propensity score–matched patients 
hospitalized with a first ACS, compared with a 
conservative approach, early invasive strategies were 
associated with a lower risk for cardiac death (cumulative 
incidence, 5.9% vs 7.6%; hazard ratio - HR, 0.75; P< 
0.001). Similar results were found for rehospitalization for 
MI (cumulative incidence, 3.4% vs 50%; HR, 0.67; P< 
0.001) and all-cause death (cumulative incidence, 7.3% vs. 
10.6%; HR, 0.65; P< 0.001) (Hansen KW et al, Ann Intern 
Med 2015;163: 737-746).  
 
In Digoxin Users Variant Alleles at Each of the 3 Loci 
in the ABCB1 Gene were Associated with an Increased 
Risk of SCD Compared With those with None or One 
T Allele, Implying that the ABCB1 Genotype Modifies 
the Risk of Cardiac Toxicity by Digoxin 
The ATP-binding cassette B1 (ABCB1) gene encodes 
P-glycoprotein, a transport protein playing an important 
role in the bioavailability of digoxin. In a total of 10,932 
persons (>45 years), 419 sudden cardiac deaths (SCDs) 
occurred during a median of 9.8 years. In non-users of 
digoxin, the risk of SCD was not different across 
genotypes. In digoxin users, homozygous T allele carriers 
of C1236T (HR 1.90; allele frequency 0.43), G2677T (HR 
1.89; allele frequency 0.44) and C3435T (HR 1.72; allele 
frequency 0.53) had a significantly increased risk of SCD 
(Niemeijer MN et al, Heart 2015;101: 1973-1979).  
 
Sweetened Beverage Consumption is Associated With 
Higher Risk of Heart Failure (HF), Possibly Having 
Implications for HF Prevention Strategies 
Among 42,400 Swedish men, aged 45-79 years, during 
a mean follow-up of 11.7 years, a total of 4113 HF events 
were identified. A positive association was observed 
between sweetened beverage consumption and risk of HF 
after adjustment for other risk factors (p for trend <0.001). 
Men who consumed >2 servings of sweetened beverages 
per day had a significantly higher risk of developing HF 
(23%) compared to men who were non-consumers 
(Rahman I et al, Heart 2015;101:1961-1965).  
 
Micra Pacing Study: Transcatheter Leadless Pacing 
Can Safely and Effectively be Applied 
Patients (n=140) requiring a VVI pacer underwent 
implantation of the Micra transcatheter pacing system, 
from the femoral vein, fixed in the right ventricle using 4 
protractible nitinol tines. Over 1.9 ± 1.8 months, 30 
adverse events related to the system or procedure occurred, 
mostly due to transient dysrhythmias or femoral access 
complications. One pericardial effusion without 
tamponade occurred after 18 device deployments. In 60 
patients followed to 3 months, mean pacing threshold was 
0.51 ± 0.22 V, and no threshold was ≥2 V. Average R-
wave was 16.1 ± 5.2 mV and impedance was 650.7 ± 130 
ohms (Ritter P et al, Eur Heart J 2015; 36: 2510-2519).  
 
Long-Term Exposure to Road Traffic Noise was 
Associated with Small Increased Risks of All-Cause 
and Cardiovascular Mortality and Morbidity in the 
General Population, Particularly for Stroke in the 
Elderly 
Median daytime exposure to road traffic noise in 
London (8.6 million inhabitants) was 55.6 dB. Daytime 
road traffic noise increased risk of hospital admission for 
stroke with relative risk (RR) 1.05 in adults, and 1.09 in 
the elderly in areas >60 vs <55 dB. Nighttime noise was 
associated with stroke admissions only among the elderly. 
Daytime noise was associated with all-cause mortality in 
adults (RR 1.04 in areas >60 vs <55 dB). Positive but non-
significant associations were seen with mortality for 
cardiovascular and ischemic heart disease, and stroke 
(Halonen JI et al, Eur Heart J 2015; 36: 2653-2661).  
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Normalization of Testosterone Level is Associated with 
Reduced Incidence of Myocardial Infarction, Stroke 
and Mortality in Men 
Of 3 groups (Gp) among 83,010 male veterans with low 
total testosterone (TT) levels, Gp1 with testosterone 
replacement therapy (TRT) and normalization of TT levels 
(n = 43,931, median age = 66 years, mean follow-up = 6.2 
years), Gp2 with TRT but without normalization of TT 
levels (n = 25,701, median age = 66 years, mean follow-up 
= 4.6 years), and Gp3 without TRT (n = 13,378, median 
age = 66 years, mean follow-up = 4.7 years), all-cause 
mortality (hazard ratio - HR: 0.44), risk of MI (HR: 0.76), 
and stroke (HR: 0.64) were lower in Gp1 vs Gp3. Also, all-
cause mortality (HR: 0.53), risk of MI (HR: 0.82), and 
stroke (HR: 0.70) were lower in Gp1 vs Gp2. There was 
no difference in MI or stroke risk between Gp2 and Gp3 
(Sharma R et al, Eur Heart J 2015; 36: 2706-2715).  
 
Reduced Appropriate Implantable Cardioverter-
Defibrillator (ICD) Therapy after Cardiac 
Resynchronization Therapy (CRT)-Induced Left 
Ventricular Function Recovery 
In 6 retrospective cohort studies (n = 1740), in patients 
with post-CRT LVEF ≥35%, rate of ICD therapy was 
significantly lower than patients with post-CRT LVEF 
<35%. Similarly, patients with post-CRT LVEF ≥45% had 
lower estimated rates of ICD therapy. Limiting analysis to 
studies discounting ICD therapies during LVEF recovery, 
patients with LVEF recovery (≥35 or ≥45%) had 
significantly lower rates of ICD therapy (Chatterjee NA et 
al, Eur Heart J 2015; 36: 2780-2789).  
 
CONTROL Study: Prostar XL-Based Vascular 
Closure in TAVI Procedures was Associated with More 
Major Vascular Complications Compared with 
ProGlide; However, In-Hospital Mortality was Similar  
Among 3138 transfemoral TAVI patients (944 matched 
/ 472 pairs), major vascular complications or in-hospital 
mortality occurred more frequently in Prostar vs ProGlide 
group (9.5 vs 5.1%, P = 0.016), driven by higher rates of 
major vascular complication (7.4 vs 1.9%, P < 0.001) in 
the Prostar group. However, in-hospital mortality was 
similar (4.9 vs 3.5%, P = 0.2). Femoral artery stenosis 
occurred less frequently in the Prostar group (3.4 vs 0.5%, 
P = 0.004), but overall, Prostar use was associated with 
higher rates of major bleeding (16.7 vs 3.2%, P < 0.001), 
acute kidney injury (17.6 vs 4.4%, P < 0.001) and with 
longer hospital stay (median 6 vs 5 days, P = 0.007) 
(Barbash IM et al, Eur Heart J 2015; 36: 3370-3379). 
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